171 results
8-K
EX-99.1
ARAV
Aravive Inc
17 Jan 24
Entry into a Material Definitive Agreement
4:22pm
-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can
8-K
EX-10.1
ARAV
Aravive Inc
17 Jan 24
Entry into a Material Definitive Agreement
4:22pm
investigation, litigation or proceeding related to or arising out of any of the foregoing, whether or not any Indemnified Person is a party thereto
8-K
EX-99.1
hh7dv
2 Aug 23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
4:18pm
8-K
aiaae6g
2 Aug 23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
4:18pm
8-K
nubugzpeayy
5 Jun 23
Regulation FD Disclosure
4:05pm
8-K
EX-99.1
b9l9 v1pyd
25 May 23
Regulation FD Disclosure
5:00pm
8-K
wx4yvkyebm2ncl4lu
25 May 23
Regulation FD Disclosure
5:00pm
8-K
3d6q1h34qam6z2wj
16 May 23
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
7:05am
8-K
EX-99.1
hn260jka
16 May 23
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
7:05am
8-K
EX-99.1
z4w2x6cb94swb 1htjxr
10 May 23
Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates
4:05pm
8-K
EX-99.1
48c4cqb8vgc2pf
11 Apr 23
Aravive Appoints Carolina Petrini as Chief Commercial Officer
7:10am
8-K
j7shve2ugokw2boaq
29 Nov 22
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
7:05am
8-K
EX-99.1
rqri740 wfq5kfmalvm2
29 Nov 22
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
7:05am